Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Expected to Rise, HC Wainwright Analyst Says

Greenwich LifeSciences (NASDAQ:GLSI) had its target price upped by investment analysts at HC Wainwright from $50.00 to $69.00 in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 419.97% from the company’s current price. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.29) EPS and Q4 2027 earnings at ($0.29) EPS.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Wall Street Zen downgraded shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Greenwich LifeSciences currently has an average rating of “Hold” and an average price target of $57.00.

Greenwich LifeSciences Stock Performance

NASDAQ:GLSI opened at $13.27 on Tuesday. Greenwich LifeSciences has a 52 week low of $7.78 and a 52 week high of $34.10. The firm’s 50-day simple moving average is $22.69 and its 200 day simple moving average is $24.50. The firm has a market cap of $194.80 million, a price-to-earnings ratio of -8.45 and a beta of 1.40.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Greenwich LifeSciences by 4.9% in the 3rd quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock valued at $2,808,000 after purchasing an additional 13,179 shares in the last quarter. Geode Capital Management LLC lifted its stake in Greenwich LifeSciences by 6.7% in the 4th quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock valued at $3,187,000 after purchasing an additional 9,568 shares during the last quarter. State Street Corp boosted its position in Greenwich LifeSciences by 19.3% in the fourth quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after buying an additional 15,831 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Greenwich LifeSciences during the second quarter worth $509,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Greenwich LifeSciences by 235.5% in the 1st quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock valued at $1,117,000 after acquiring an additional 32,657 shares during the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.